Whipplewood Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$903 Sell
3
-26
-90% -$7.84K ﹤0.01% 560
2026
Q1
$9.6K Buy
+29
New +$9.87K 0.01% 497
2025
Q3
Sell
-42
Closed -$13.7K 333
2025
Q2
$13.7K Sell
42
-63
-60% -$17.4K 0.01% 520
2025
Q1
$10.3K Buy
105
+71
+209% +$18.2K 0.01% 559
2024
Q4
$8K Buy
+34
New +$8.94K ﹤0.01% 592

Other funds holding ALNY

Whipplewood Advisors's ALNY Position: Q2 2026 in Review

Whipplewood Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 90% in Q2 2026, selling an estimated $7.84K and leaving 3 shares worth $903. The position accounts for ﹤0.01% of the portfolio, ranked #560.

Whipplewood Advisors first reported a position in ALNY in Q4 2024 and has held it in 5 quarters since. The position peaked at $13.7K in Q2 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Whipplewood Advisors held 3 shares of Alnylam Pharmaceuticals worth $903 as of Q2 2026.
  • Whipplewood Advisors sold 26 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $7.84K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Whipplewood Advisors's portfolio in Q2 2026, its #560 holding.
  • Whipplewood Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Whipplewood Advisors's Alnylam Pharmaceuticals position peaked at $13.7K in Q2 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Whipplewood Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.